Overview
AYTU market data
Price History
AYTU price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.65 – $3.07 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $23.3 · P/B 1.03 · P/S 0.41.
Company news
Aytu BioPharma And And Lannett Terminate Metadate Agreement Effective June 23, 2026; Co. To Continue Selling Existing Metadate Inventory And Pay Royalties Until Sales CeaseBenzinga · Jun 25, 2026, 8:45 PM
8-K filing — AYTU BIOPHARMA, INC (AYTU)SEC EDGAR · Jun 25, 2026, 8:31 PM
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5Benzinga · Jun 11, 2026, 9:44 AM
Full Transcript: Aytu BioPharma Q3 2026 Earnings CallBenzinga · May 13, 2026, 9:39 PM
Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M EstimateBenzinga · May 13, 2026, 8:07 PM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM